PS02.20 Subsequent Therapies Post-Afatinib among Patients with EGFR Mutation-Positive (egfrm+) NSCLC in LUX-Lung 3, 6 and 7
L. V. Sequist,Y. Wu,M. Schuler,T. Kato,J. C. Yang,H. Tanaka,T. Hida,S. Lu,K. Park,L. Paz-Ares,S. Laurie,J. Bennouna,D. Moro Sibilot,A. Maerten,W. Tang,E. Ehrnrooth,N. Yamamoto,K. Nakagawa
DOI: https://doi.org/10.1016/j.jtho.2017.09.058
IF: 20.121
2017-01-01
Journal of Thoracic Oncology
Abstract:Acquired resistance invariably develops following front-line EGFR TKI treatment, and necessitates subsequent therapies for patients with EGFRm+ NSCLC. However, limited clinical data are available to help guide treatment decisions regarding sequential therapy. Here we evaluated the outcomes of subsequent therapies, including other EGFR TKIs and chemotherapy, after first-line afatinib or chemotherapy in the LUX-Lung (LL) 3, 6 and 7 randomized trials. We retrospectively assessed subsequent therapy outcomes in patients with common EGFR mutations, who were randomized to first-line afatinib or chemotherapy in LL3, 6 and 7. Data were prospectively collected as study follow-up information. Treatment duration was assessed by descriptive medians or Kaplan–Meier estimates. Biopsies at afatinib discontinuation were not required. Of the 553 patients with common EGFR mutations who received first-line afatinib and later discontinued it, 394 (71%) received second-line treatment, consisting of platinum-based chemotherapy in 252/553 (46%), first-generation EGFR TKI monotherapy in 49/553 (9%), single-agent chemotherapy in 39/553 (7%), and other treatments (including osimertinib) in 54/553 (10%) patients. Median time on second-line treatment was 2.9 months (i.e. ∼4 cycles) for platinum-based and 1.4 months for single-agent chemotherapy, with no relevant difference between Del19 and L858R EGFR mutation subgroups. Among 186 (34%) patients who received subsequent first-generation EGFR TKI monotherapy, median time on treatment in any line was 3.9 months. Of 212 patients randomized to first-line chemotherapy in LL3 and LL6, 117 (55%) received first-generation EGFR TKI monotherapy in second-line, with a median time on treatment of 11.2 months. Notably, 34 patients received osimertinib after first-line afatinib, the majority in third or later lines; median time on osimertinib treatment was 31.5 months (95% CI 16.8–31.5 months); median OS for these patients is not yet evaluable. The majority of patients (71%) who received first-line afatinib in LL3, 6 and 7 received subsequent therapies, with no relevant difference in second-line treatment duration by Del19/L858R mutation subgroup. Treatment with a first-generation TKI was common, with good outcome. Time on osimertinib treatment after first-line afatinib was unexpectedly long among 34 patients, which warrants further examination. Overall, these findings support treatment sequencing with first-line afatinib followed by subsequent therapies, including osimertinib.